Delivery Order SPE2DB22D2006-SPE2DB25FW4EE
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,249.80 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed-price contract valued at $8,401.76, with an ultimate completion date of August 20, 2025. This non-set-aside competitive award was issued on August 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,985.98 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units). This non-set-aside, competitively awarded contract utilizes firm fixed price terms with an ultimate completion date of August 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery from its Pennsylvania facility. This delivery order...
- The Defense Logistics Agency awarded a competitive delivery order valued at $4,651.90 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 12, 2025, with an ultimate completion date of September 15, 2025. This order will be fulfilled from the contractor's corporate office location in Conshohocken, Pennsylvania, using firm fixed pricing with no set-aside designation. The award represents a child delivery order under AmerisourceBergen's existing...
- The Defense Logistics Agency (DLA) awarded a $25,962.25 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Xifaxan 550 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, reflecting the vendor's established capability to meet federal pharmaceutical procurement requirements. The contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count) under a firm fixed price contract valued at $3,513.96, with an ultimate completion date of August 11, 2025. This non-set-aside award represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,419.46 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) on August 20, 2025, with completion expected by August 21, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a competitive procurement action under AmerisourceBergen's existing Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $20,573.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is categorized as a child contract under AmerisourceBergen's broader federal contract portfolio. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $12,991.41 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on August 21, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $7,318.28. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with a place of performance in Conshohocken, Pennsylvania, and an ultimate completion date of August 22, 2025. The contract is issued as a child order under AmerisourceBergen's larger...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW4EEDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed price arrangement. The contract, valued at $4,363.07, was awarded on September 12, 2025, with an ultimate completion date of September 15, 2025. This non-competitive delivery order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support contract for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies a comprehensive range of pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive federal contract portfolio with DLA demonstrates its capability to fulfill diverse medical supply requirements through open competition, with previous awards covering specialty medications, vaccines, medical devices, and brand-name and generic drugs across multiple therapeutic domains. This delivery order for Xifaxan, an antibiotic medication, reflects the company's ongoing role as a primary pharmaceutical supplier supporting military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 9/12/25 |